Table 1.
Manufacturer's specifications for SARS-CoV-2 CLIA serology platforms at the time of the validation study.
| Assay | DiaSorin IgG | Ortho IgG | Ortho T | Siemens T | Abbott IgG | Roche T |
|---|---|---|---|---|---|---|
| Analyzer used | LIAISONTM XL | VITROSTM XT 7600 | VITROSTM XT 7600 | ADVIA Centaur® XP | ARCHITECTTM | cobasTM e601 |
| Target epitope | S1 and S2 | S | S1 | S1 Receptor Binding Domain | N | N |
| Target immunoglobulin | IgG | IgG | Total Ab | IgM and IgG | IgG | Total Ab |
| Sensitivity at >14 days post-onset (n) | 97.6% (41) | 89% (65) | 100% (49) | 100% (47) | 100% (88) | 100% (29) |
| Specificity (n) | 98.5% (1,090) |
100% (407) |
100% (400) |
99.8% (1,589) | 99.6% (1,070) | 99.8% (5,272) |
Abbreviations: S=spike protein; N=nucleocapsid protein; Ab=antibody